| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| holding | SAGE | Common Stock | 27.1K | Apr 1, 2025 | Direct | F1 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| holding | SAGE | Stock Options (Right to buy) | Apr 1, 2025 | Common Stock | 36K | $6.97 | Direct | F2 | ||||||
| holding | SAGE | Stock Options (Right to buy) | Apr 1, 2025 | Common Stock | 13.1K | $22.20 | Direct | F3 | ||||||
| holding | SAGE | Stock Options (Right to buy) | Apr 1, 2025 | Common Stock | 15K | $23.02 | Direct | F4 | ||||||
| holding | SAGE | Stock Options (Right to buy) | Apr 1, 2025 | Common Stock | 3.8K | $19.76 | Direct | F5 | ||||||
| holding | SAGE | Stock Options (Right to buy) | Apr 1, 2025 | Common Stock | 14.3K | $45.28 | Direct | F6 | ||||||
| holding | SAGE | Stock Options (Right to buy) | Apr 1, 2025 | Common Stock | 7.25K | $39.59 | Direct | F7 | ||||||
| holding | SAGE | Stock Options (Right to buy) | Apr 1, 2025 | Common Stock | 5.33K | $43.04 | Direct | F8 | ||||||
| holding | SAGE | Stock Options (Right to buy) | Apr 1, 2025 | Common Stock | 4.95K | $39.87 | Direct | F9 | ||||||
| holding | SAGE | Stock Options (Right to buy) | Apr 1, 2025 | Common Stock | 1K | $28.63 | Direct | F10 |
| Id | Content |
|---|---|
| F1 | Consists of (i) 20,808 shares of Common Stock and (ii) 6,300 shares of Common Stock issuable under restricted stock units ("RSUs") awarded to the Reporting Person pursuant to the Sage Therapeutics, Inc. 2014 Stock Option and Incentive Plan (the "2014 Plan") that vest periodically subject to the Reporting Person's continued service. Each RSU represents the right to receive one share of Common Stock upon vesting. |
| F10 | This option was granted on February 8, 2016, pursuant to the 2014 Plan. The shares underlying the option have vested in full |
| F2 | This option was granted on January 16, 2025, pursuant to the Sage Therapeutics Inc. 2024 Equity Incentive Plan. The shares underlying the option vest over four years, with 25% of the shares vesting on January 16, 2026, and the remaining shares vesting in equal monthly installments thereafter, subject to the Reporting Person's continued service. |
| F3 | This option was granted on February 21, 2024, pursuant to the 2014 Plan. The shares underlying the option vest in equal monthly installments over 18 months, with the first installment vested on March 21, 2024, and the remaining shares vesting in equal monthly installments thereafter, subject to the Reporting Person's continued service. |
| F4 | This option was granted on February 13, 2024, pursuant to the 2014 Plan. The shares underlying the option vest over four years, with 25% of the shares vested on February 13, 2025, and the remaining shares vesting in equal monthly installments thereafter, subject to the Reporting Person's continued service. |
| F5 | This option was granted on October 2, 2023, pursuant to the 2014 Plan. The shares underlying the option vest over four years, with 25% of the shares vested on September 16, 2024, and the remaining shares vesting in equal monthly installments thereafter, subject to the Reporting Person's continued service. |
| F6 | This option was granted on February 13, 2023, pursuant to the 2014 Plan. The shares underlying the option vest over four years, with 25% of the shares vested on February 13, 2024, and the remaining shares vesting in equal monthly installments thereafter, subject to the Reporting Person's continued service. |
| F7 | This option was granted on October 3, 2022, pursuant to the 2014 Plan. The shares underlying the option vest over four years, with 25% of the shares vested on October 1, 2023, and the remaining shares vesting in equal monthly installments thereafter, subject to the Reporting Person's continued service. |
| F8 | This option was granted on February 11, 2022, pursuant to the 2014 Plan. The shares underlying the option vest over four years, with 25% of the shares vested on February 11, 2023, and the remaining shares vesting in equal monthly installments thereafter, subject to the Reporting Person's continued service. |
| F9 | This option was granted on April 28, 2020, pursuant to the 2014 Plan. The shares underlying the option have vested in full. |
Chief Scientific Officer and Interim Head of R&D